Adcendo ApS
Core data
Name | Adcendo ApS |
Address | Nordre Fasanvej 215, 2000, Frederiksberg |
Founded | Jul 1, 2017 |
Employees (CVR) | 48 |
Locations (P-units) | 1View locations |
Website | https://adcendo.com/ |
 LinkedIn | adcendo |
Branch | Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000) |
Name | Adcendo ApS |
Address | Nordre Fasanvej 215, 2000, Frederiksberg |
Founded | Jul 1, 2017 |
Employees (CVR) | 48 |
Locations (P-units) | 1View locations |
Website | https://adcendo.com/ |
| LinkedIn | adcendo |
Branch | Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000) |
Keep track of Adcendo ApS
Description
Adcendo ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts. It develops first- and potential best-in-class antibody-drug conjugates for cancers with high unmet medical needs.
Adcendo develops a pipeline of antibody-drug conjugates targeting cancers with high unmet medical needs and is advancing three ADCs in the clinic: ADCE-T02, ADCE-D01, and ADCE-B05.
Company's own description on virk.dk
Adcendo is a global clinical-stage biotechnology company dedicated to developing transformative first- and best-in-class antibody–drug conjugate (ADC) therapies for cancers with high unmet medical need. Our team of highly specialized experts pioneers the development of novel ADCs through a combination of deep understanding of target biology, optimized linker–payload technologies, and rationally designed clinical development strategies. We collaborate with a network of international scientific and clinical experts, technology and manufacturing partners, and life sciences investors.
Products & services
ADCE-T02 antibody-drug conjugate targeting Tissue Factor · ADCE-D01 antibody-drug conjugate targeting uPARAP · ADCE-B05 antibody-drug conjugate with undisclosed target
Industries
Biotechnology · Biopharmaceuticals · Oncology · Drug development
Customer types
Cancer patients · Patients with cancers with high unmet medical needs
Financials
| Reporting period | 2025DKK | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross profit | -254,743,000 | ||||||||
| Operating profit | -361,292,000 | ||||||||
| Profit before tax | -388,479,000 | ||||||||
| Net income | -382,979,000 | ||||||||
| Total assets | 881,678,000 | ||||||||
| Equity | 742,809,000 | ||||||||
| Avg. employees | 54 | ||||||||
2018–2025 Unlock financial history | |||||||||
Datapublica Risk Score
What goes into the assessment
Financials
Equity ratio, profitability, and liquidity
Accounts and history
Late filings and previous financial distress
Owners and management
Past bankruptcies and owners’ other companies
Company and connections
Age, industry, and shared addresses or contact details
Standard: Score and risk bandPro: Also a detailed explanation of the factors
Gazelle
Loading gazelle status…
Børsen Gazelle is Dagbladet Børsen's award. Datapublica is not affiliated with Børsen. Calculated statuses are Datapublica's own analysis of public CVR financial-statement data.
Founders
| Founder | Registered as founder | Current roles | Ownership |
|---|---|---|---|
| Christoffer Fagernæs Nielsen | Registered as founderJul 1, 2017 | Current roles — | Ownership — |
| Lars Henning Milman Engelholm | Registered as founderJul 1, 2017 | Current roles — | Ownership — |
| Niels Behrendt | Registered as founderJul 1, 2017 | Current roles — | Ownership — |
People
| Person | Roles | Titles |
|---|---|---|
| Pieter Jeroen Bakker | Roles Board | TitlesBESTYRELSESMEDLEM |
| Lasse René Sørensen | Roles Management | TitlesDIREKTØR |
| Lone Harild Ottesen | Roles Management | TitlesDIREKTØR |
| Pernille Kristine Hemmingsen | Roles Management | TitlesDIREKTØR |
Auditor
| Audit firm | Auditor | Role | From |
|---|---|---|---|
| PricewaterhouseCoopers | AuditorAnette Beltrão-Primdahl | RoleState Authorised Public Accountant | FromMay 13, 2026 |
| PricewaterhouseCoopers | AuditorTorben Jensen | RoleState Authorised Public Accountant | FromMay 13, 2026 |
| PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab | Auditor— | Role— | FromMay 13, 2026 |
Legal owners
| Owner | Ownership | Voting rights | From |
|---|---|---|---|
Unknown Other Participant | Ownership10–14.99 % | Voting rights10 % | FromMar 16, 2026 |
Unknown Other Participant | Ownership5–9.99 % | Voting rights5 % | FromMar 16, 2026 |
Unknown Other Participant | Ownership5–9.99 % | Voting rights5 % | FromMar 16, 2026 |
Unknown Other Participant | Ownership5–9.99 % | Voting rights5 % | FromMar 16, 2026 |
Unknown Other Participant | Ownership5–9.99 % | Voting rights5 % | FromMar 16, 2026 |
| Ownership5–9.99 % | Voting rights5 % | FromMar 16, 2026 | |
Unknown Other Participant | Ownership5–9.99 % | Voting rights5 % | FromMar 16, 2026 |
Unknown Other Participant | Ownership5–9.99 % | Voting rights5 % | FromMar 16, 2026 |
Unknown Other Participant | Ownership5–9.99 % | Voting rights5 % | FromMar 16, 2026 |
Unknown Other Participant | Ownership5–9.99 % | Voting rights5 % | FromMar 16, 2026 |
Ultimate owners
| Name | Ownership through | Calculated ownership |
|---|---|---|
| 🇺🇸TCG Crossover Fund II, L.P. | Ownership through Direct | 10–14.99 % |
| 🇳🇱Coöperatieve Gilde Healthcare V U.A. | Ownership through Direct | 5–9.99 % |
| 🇱🇺Dawn Holdco SCSp | Ownership through Direct | 5–9.99 % |
| 🇺🇸Healthcap VIII L.P. | Ownership through Direct | 5–9.99 % |
| 🇫🇷Jeito II S.L.P | Ownership through Direct | 5–9.99 % |
| NOVO NORDISK FONDEN | Ownership through | 5–9.99 % |
| 🇮🇱Pontifax (Israel) VI L.P. | Ownership through Direct | 5–9.99 % |
| 🇺🇸RA Capital Healthcare Fund, L.P. | Ownership through Direct | 5–9.99 % |
| 🇱🇺TPG LSI Rise Athletic S.à r.l. | Ownership through Direct | 5–9.99 % |
| 🇪🇸YSIOS BIOFUND III, FCRE | Ownership through Direct | 5–9.99 % |